Review



mouse anti human ccnd1 antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Proteintech mouse anti human ccnd1 antibody
    a. Heatmap depicting the top 20 differentially expressed genes between STAG2 wildtype and mutant populations. b. Using gene set enrichment analysis (GSEA), only the “HALLMARK_TNFA_SIGNALING_VIA_NFKB” gene set was upregulated in wildtype compared to mutant (Normalised enrichment score: 1.75, False discovery rate q -value: 0.078). c. On immunofluorescence staining, we observed increased proliferation of wildtype organoids relative to STAG2 mutants when stained with anti-KI67 antibody. d. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. e. We also observed increased tumorigenicity of wildtype organoids relative to STAG2 mutants when stained with <t>anti-CCND1</t> antibody. f. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. Scale bars are 50µm. All experiments were performed with N = 3 biological replicates.
    Mouse Anti Human Ccnd1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1613 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+ccnd1+antibody/Cyclin+D1+Antibody/pmc12527130-160-28-34
    Average 96 stars, based on 1613 article reviews
    mouse anti human ccnd1 antibody - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells"

    Article Title: STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells

    Journal: PLOS One

    doi: 10.1371/journal.pone.0332499

    a. Heatmap depicting the top 20 differentially expressed genes between STAG2 wildtype and mutant populations. b. Using gene set enrichment analysis (GSEA), only the “HALLMARK_TNFA_SIGNALING_VIA_NFKB” gene set was upregulated in wildtype compared to mutant (Normalised enrichment score: 1.75, False discovery rate q -value: 0.078). c. On immunofluorescence staining, we observed increased proliferation of wildtype organoids relative to STAG2 mutants when stained with anti-KI67 antibody. d. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. e. We also observed increased tumorigenicity of wildtype organoids relative to STAG2 mutants when stained with anti-CCND1 antibody. f. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. Scale bars are 50µm. All experiments were performed with N = 3 biological replicates.
    Figure Legend Snippet: a. Heatmap depicting the top 20 differentially expressed genes between STAG2 wildtype and mutant populations. b. Using gene set enrichment analysis (GSEA), only the “HALLMARK_TNFA_SIGNALING_VIA_NFKB” gene set was upregulated in wildtype compared to mutant (Normalised enrichment score: 1.75, False discovery rate q -value: 0.078). c. On immunofluorescence staining, we observed increased proliferation of wildtype organoids relative to STAG2 mutants when stained with anti-KI67 antibody. d. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. e. We also observed increased tumorigenicity of wildtype organoids relative to STAG2 mutants when stained with anti-CCND1 antibody. f. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. Scale bars are 50µm. All experiments were performed with N = 3 biological replicates.

    Techniques Used: Mutagenesis, Immunofluorescence, Staining, Cell Culture

    Related Articles

    Mutagenesis:

    Article Title: STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells
    Article Snippet: For immunofluorescent experiments in and , unless otherwise stated, steps were similar as above.For immunofluorescent experiments in and , unless otherwise stated, steps were similar as above.. Primary antibodies used included rabbit anti-human STAG2 antibody (1:100, 19837–1-AP, Proteintech, USA), mouse anti-human KI67 antibody (1:500, 66555–6-Ig, Proteintech, USA), mouse anti-human P53 antibody (1:400, 60283–2-Ig, Proteintech, USA), mouse anti-human CCND1 antibody (1:100, 60186–1-Ig, Proteintech, USA), mouse anti-human TERT antibody (1: 100, MA5−16033, Invitrogen, USA), mouse anti-human KRAS antibody (1:250, 415700, Invitrogen, USA), and mouse anti-human TNFα antibody (1:50, MA5−23720, Invitrogen, USA).. Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1 μg/ml, D1306, Invitrogen, USA).Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1..

    Article Title: STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells.
    Article Snippet: For immunofluorescent experiments in Figs 4 and 5, unless otherwise stated, steps were similar as above.For immunofluorescent experiments in Figs 4 and 5, unless otherwise stated, steps were similar as above.. Primary antibodies used included rabbit anti-human STAG2 antibody (1:100, 19837–1-AP, Proteintech, USA), mouse anti-human KI67 antibody (1:500, 66555–6-Ig, Proteintech, USA), mouse anti-human P53 antibody (1:400, 60283–2-Ig, Proteintech, USA), mouse anti-human CCND1 antibody (1:100, 60186–1-Ig, Proteintech, USA), mouse anti-human TERT antibody (1: 100, MA5−16033, Invitrogen, USA), mouse anti-human KRAS antibody (1:250, 415700, Invitrogen, USA), and mouse anti-human TNFα antibody (1:50, MA5−23720, Invitrogen, USA).. Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1 μg/ml, D1306, Invitrogen, USA).Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1..

    Immunofluorescence:

    Article Title: STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells
    Article Snippet: For immunofluorescent experiments in and , unless otherwise stated, steps were similar as above.For immunofluorescent experiments in and , unless otherwise stated, steps were similar as above.. Primary antibodies used included rabbit anti-human STAG2 antibody (1:100, 19837–1-AP, Proteintech, USA), mouse anti-human KI67 antibody (1:500, 66555–6-Ig, Proteintech, USA), mouse anti-human P53 antibody (1:400, 60283–2-Ig, Proteintech, USA), mouse anti-human CCND1 antibody (1:100, 60186–1-Ig, Proteintech, USA), mouse anti-human TERT antibody (1: 100, MA5−16033, Invitrogen, USA), mouse anti-human KRAS antibody (1:250, 415700, Invitrogen, USA), and mouse anti-human TNFα antibody (1:50, MA5−23720, Invitrogen, USA).. Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1 μg/ml, D1306, Invitrogen, USA).Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1..

    Article Title: STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells.
    Article Snippet: For immunofluorescent experiments in Figs 4 and 5, unless otherwise stated, steps were similar as above.For immunofluorescent experiments in Figs 4 and 5, unless otherwise stated, steps were similar as above.. Primary antibodies used included rabbit anti-human STAG2 antibody (1:100, 19837–1-AP, Proteintech, USA), mouse anti-human KI67 antibody (1:500, 66555–6-Ig, Proteintech, USA), mouse anti-human P53 antibody (1:400, 60283–2-Ig, Proteintech, USA), mouse anti-human CCND1 antibody (1:100, 60186–1-Ig, Proteintech, USA), mouse anti-human TERT antibody (1: 100, MA5−16033, Invitrogen, USA), mouse anti-human KRAS antibody (1:250, 415700, Invitrogen, USA), and mouse anti-human TNFα antibody (1:50, MA5−23720, Invitrogen, USA).. Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1 μg/ml, D1306, Invitrogen, USA).Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1..

    Staining:

    Article Title: STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells
    Article Snippet: For immunofluorescent experiments in and , unless otherwise stated, steps were similar as above.For immunofluorescent experiments in and , unless otherwise stated, steps were similar as above.. Primary antibodies used included rabbit anti-human STAG2 antibody (1:100, 19837–1-AP, Proteintech, USA), mouse anti-human KI67 antibody (1:500, 66555–6-Ig, Proteintech, USA), mouse anti-human P53 antibody (1:400, 60283–2-Ig, Proteintech, USA), mouse anti-human CCND1 antibody (1:100, 60186–1-Ig, Proteintech, USA), mouse anti-human TERT antibody (1: 100, MA5−16033, Invitrogen, USA), mouse anti-human KRAS antibody (1:250, 415700, Invitrogen, USA), and mouse anti-human TNFα antibody (1:50, MA5−23720, Invitrogen, USA).. Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1 μg/ml, D1306, Invitrogen, USA).Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1..

    Article Title: STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells.
    Article Snippet: For immunofluorescent experiments in Figs 4 and 5, unless otherwise stated, steps were similar as above.For immunofluorescent experiments in Figs 4 and 5, unless otherwise stated, steps were similar as above.. Primary antibodies used included rabbit anti-human STAG2 antibody (1:100, 19837–1-AP, Proteintech, USA), mouse anti-human KI67 antibody (1:500, 66555–6-Ig, Proteintech, USA), mouse anti-human P53 antibody (1:400, 60283–2-Ig, Proteintech, USA), mouse anti-human CCND1 antibody (1:100, 60186–1-Ig, Proteintech, USA), mouse anti-human TERT antibody (1: 100, MA5−16033, Invitrogen, USA), mouse anti-human KRAS antibody (1:250, 415700, Invitrogen, USA), and mouse anti-human TNFα antibody (1:50, MA5−23720, Invitrogen, USA).. Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1 μg/ml, D1306, Invitrogen, USA).Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1..

    Cell Culture:

    Article Title: STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells
    Article Snippet: For immunofluorescent experiments in and , unless otherwise stated, steps were similar as above.For immunofluorescent experiments in and , unless otherwise stated, steps were similar as above.. Primary antibodies used included rabbit anti-human STAG2 antibody (1:100, 19837–1-AP, Proteintech, USA), mouse anti-human KI67 antibody (1:500, 66555–6-Ig, Proteintech, USA), mouse anti-human P53 antibody (1:400, 60283–2-Ig, Proteintech, USA), mouse anti-human CCND1 antibody (1:100, 60186–1-Ig, Proteintech, USA), mouse anti-human TERT antibody (1: 100, MA5−16033, Invitrogen, USA), mouse anti-human KRAS antibody (1:250, 415700, Invitrogen, USA), and mouse anti-human TNFα antibody (1:50, MA5−23720, Invitrogen, USA).. Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1 μg/ml, D1306, Invitrogen, USA).Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1..

    Article Title: STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells.
    Article Snippet: For immunofluorescent experiments in Figs 4 and 5, unless otherwise stated, steps were similar as above.For immunofluorescent experiments in Figs 4 and 5, unless otherwise stated, steps were similar as above.. Primary antibodies used included rabbit anti-human STAG2 antibody (1:100, 19837–1-AP, Proteintech, USA), mouse anti-human KI67 antibody (1:500, 66555–6-Ig, Proteintech, USA), mouse anti-human P53 antibody (1:400, 60283–2-Ig, Proteintech, USA), mouse anti-human CCND1 antibody (1:100, 60186–1-Ig, Proteintech, USA), mouse anti-human TERT antibody (1: 100, MA5−16033, Invitrogen, USA), mouse anti-human KRAS antibody (1:250, 415700, Invitrogen, USA), and mouse anti-human TNFα antibody (1:50, MA5−23720, Invitrogen, USA).. Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1 μg/ml, D1306, Invitrogen, USA).Slides were then washed in PBS, before the addition of CoraLite488-conjugated Goat Anti-Rabbit antibody (1:500, SA00013−2, Proteintech, USA), Multi-rAbTM CoraLite® Plus 647-Goat Anti-Mouse antibody (1:500, RGAM005, Proteintech, USA), and DAPI(0.1..



    Similar Products

    mouse anti human ccnd1 antibody  (Proteintech)
    96
    Proteintech mouse anti human ccnd1 antibody
    a. Heatmap depicting the top 20 differentially expressed genes between STAG2 wildtype and mutant populations. b. Using gene set enrichment analysis (GSEA), only the “HALLMARK_TNFA_SIGNALING_VIA_NFKB” gene set was upregulated in wildtype compared to mutant (Normalised enrichment score: 1.75, False discovery rate q -value: 0.078). c. On immunofluorescence staining, we observed increased proliferation of wildtype organoids relative to STAG2 mutants when stained with anti-KI67 antibody. d. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. e. We also observed increased tumorigenicity of wildtype organoids relative to STAG2 mutants when stained with <t>anti-CCND1</t> antibody. f. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. Scale bars are 50µm. All experiments were performed with N = 3 biological replicates.
    Mouse Anti Human Ccnd1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+ccnd1+antibody/Cyclin+D1+Antibody/pmc12527130-160-28-34
    Average 96 stars, based on 1 article reviews
    mouse anti human ccnd1 antibody - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    mouse anti human monoclonal ccnd1  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology mouse anti human monoclonal ccnd1
    Figure 3. miR-623 directly targets <t>cyclin</t> <t>D1</t> <t>(CCND1)</t> in GC. (A) Wild-type (WT) and mutated (MUT) miR-623 binding sequences in the 3¢-untranslated region (3¢-UTR) of CCND1. (B) RT-qPCR and (C) Western blot were performed to determine the mRNA and protein levels of CCND1 in SGC-7901 and BGC-823 cells transfected with miR-623 mimic or miR-NC. *p < 0.05 compared with miR-NC. miR-623 or miR-NC was transfected in (D) SGC-7901 and (E) BGC-823 cells with psiCHECK-WT-CCND1-3¢-UTR or psiCHECK-MUT-CCND1-3¢-UTR. Relative luciferase activity levels were measured at 48 h posttransfection. *p < 0.05 compared with miR-NC.
    Mouse Anti Human Monoclonal Ccnd1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+ccnd1+antibody/cyclin+D1+Antibody/10__3727_slash_096504018x15193469240508-98-3-27
    Average 96 stars, based on 1 article reviews
    mouse anti human monoclonal ccnd1 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    mouse anti human ccnd1 monoclonal antibody  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology mouse anti human ccnd1 monoclonal antibody
    Figure 3. <t>CCND1</t> is a direct target of miR‑720 in pancreatic cancer. (A) Wild type and mutant of putative miR‑720 binding sites in the 3'‑untranslated region (3'‑UTR) of CCND1. (B) Relative luciferase activities in Panc‑1 and Sw1990 cells transfected with miR‑720 mimics or NC, together with pMIR‑CCND1‑3'‑UTR WT or pMIR‑CCND1‑3'‑UTR MUT. *P<0.05 compared with NC. (C and D) RT‑qPCR and Western blot analyses showed that miR‑720 overexpression decreased CCND1 mRNA and protein expression levels in Panc‑1 and Sw1990 cells. *P<0.05 compared with NC.
    Mouse Anti Human Ccnd1 Monoclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+ccnd1+antibody/cyclin+D1+Antibody/pm28990111-79-25-33
    Average 96 stars, based on 1 article reviews
    mouse anti human ccnd1 monoclonal antibody - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    mouse monoclonal antibody against human ccnd1  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc mouse monoclonal antibody against human ccnd1
    Figure 3. <t>CCND1</t> is a potential target of miR-34a. (A) Schematic of the putative miR-34a binding site in the 3'-UTR region of CCND1 and interspecies conservation of seed matching sequences (gray box). (B) Diagram of CCND1 3'-UTR containing the reporter constructs. (C) Luciferase reporter assays in HEp-2 cells co-transfected with wt/mut 3'-UTR and miR-34a/miR-Ctrl as indicated. (D) Expression levels of CCND1 were tested after miR-34a transfection at 50 nM in HEp-2 cells by western blotting assay. *P<0.05 compared with the control. 3'-UTR, 3'-untranslated region.
    Mouse Monoclonal Antibody Against Human Ccnd1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+ccnd1+antibody/Cyclin+D1+Rabbit+mAb/pm27220728-102-28-34
    Average 96 stars, based on 1 article reviews
    mouse monoclonal antibody against human ccnd1 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    ccnd1 mouse anti human cyclin d1 cell signaling  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc ccnd1 mouse anti human cyclin d1 cell signaling
    Figure 3. <t>CCND1</t> is a potential target of miR-34a. (A) Schematic of the putative miR-34a binding site in the 3'-UTR region of CCND1 and interspecies conservation of seed matching sequences (gray box). (B) Diagram of CCND1 3'-UTR containing the reporter constructs. (C) Luciferase reporter assays in HEp-2 cells co-transfected with wt/mut 3'-UTR and miR-34a/miR-Ctrl as indicated. (D) Expression levels of CCND1 were tested after miR-34a transfection at 50 nM in HEp-2 cells by western blotting assay. *P<0.05 compared with the control. 3'-UTR, 3'-untranslated region.
    Ccnd1 Mouse Anti Human Cyclin D1 Cell Signaling, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+ccnd1+antibody/N-Myc+Antibody/pmc05204355__supp_30__23__2637_Supplemental_Data-35-18-23
    Average 95 stars, based on 1 article reviews
    ccnd1 mouse anti human cyclin d1 cell signaling - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    mouse anti human cyclin d1  (OriGene)
    90
    OriGene mouse anti human cyclin d1
    Figure 5. miR-129-5p directly targets APC-mRNA at 39-UTR and protein expression of genes regulated by miR-129-5p. (A) The predicted miR-129-5p target site on the APC 39-UTR. (B) Luciferase reporter gene assay measuring interactions between miR-129-5p and its binding site on the 39UTR of APC in HEK293T cells. The expression of the APC reporter was significantly decreased 53% in miR-129-5p-transfected cells compared to control cells. *P,0.05. (C) Luciferase reporter gene assay for measuring interactions between miR-129-5p and 39UTR of the APC mutant in HEK293T cells. There was no significant difference between groups (P.0.05). Luciferase experiments were repeated 3 times. (D) APC expression in the cells treated with ASO-miR-129-5p was increased compared to that in the controls. *P,0.05. (E) <t>cyclin</t> <t>D1</t> expression in the cells treated with ASO- miR-129-5p was lower compared to controls. *P,0.05. (F) c-myc expression in the cells treated with ASO-miR-129-5p was lower compared to controls. *P,0.05. doi:10.1371/journal.pone.0077829.g005
    Mouse Anti Human Cyclin D1, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+ccnd1+antibody/Cyclin+D1+(CCND1)+Mouse+Monoclonal+Antibody/pm24194897-106-4-9
    Average 90 stars, based on 1 article reviews
    mouse anti human cyclin d1 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    mouse monoclonal anti human ccnd1  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc mouse monoclonal anti human ccnd1
    Figure 5. miR-129-5p directly targets APC-mRNA at 39-UTR and protein expression of genes regulated by miR-129-5p. (A) The predicted miR-129-5p target site on the APC 39-UTR. (B) Luciferase reporter gene assay measuring interactions between miR-129-5p and its binding site on the 39UTR of APC in HEK293T cells. The expression of the APC reporter was significantly decreased 53% in miR-129-5p-transfected cells compared to control cells. *P,0.05. (C) Luciferase reporter gene assay for measuring interactions between miR-129-5p and 39UTR of the APC mutant in HEK293T cells. There was no significant difference between groups (P.0.05). Luciferase experiments were repeated 3 times. (D) APC expression in the cells treated with ASO-miR-129-5p was increased compared to that in the controls. *P,0.05. (E) <t>cyclin</t> <t>D1</t> expression in the cells treated with ASO- miR-129-5p was lower compared to controls. *P,0.05. (F) c-myc expression in the cells treated with ASO-miR-129-5p was lower compared to controls. *P,0.05. doi:10.1371/journal.pone.0077829.g005
    Mouse Monoclonal Anti Human Ccnd1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+ccnd1+antibody/CDK6+Mouse+mAb/pm23325924-101-6-4
    Average 96 stars, based on 1 article reviews
    mouse monoclonal anti human ccnd1 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    a. Heatmap depicting the top 20 differentially expressed genes between STAG2 wildtype and mutant populations. b. Using gene set enrichment analysis (GSEA), only the “HALLMARK_TNFA_SIGNALING_VIA_NFKB” gene set was upregulated in wildtype compared to mutant (Normalised enrichment score: 1.75, False discovery rate q -value: 0.078). c. On immunofluorescence staining, we observed increased proliferation of wildtype organoids relative to STAG2 mutants when stained with anti-KI67 antibody. d. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. e. We also observed increased tumorigenicity of wildtype organoids relative to STAG2 mutants when stained with anti-CCND1 antibody. f. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. Scale bars are 50µm. All experiments were performed with N = 3 biological replicates.

    Journal: PLOS One

    Article Title: STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells

    doi: 10.1371/journal.pone.0332499

    Figure Lengend Snippet: a. Heatmap depicting the top 20 differentially expressed genes between STAG2 wildtype and mutant populations. b. Using gene set enrichment analysis (GSEA), only the “HALLMARK_TNFA_SIGNALING_VIA_NFKB” gene set was upregulated in wildtype compared to mutant (Normalised enrichment score: 1.75, False discovery rate q -value: 0.078). c. On immunofluorescence staining, we observed increased proliferation of wildtype organoids relative to STAG2 mutants when stained with anti-KI67 antibody. d. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. e. We also observed increased tumorigenicity of wildtype organoids relative to STAG2 mutants when stained with anti-CCND1 antibody. f. Fluorescent intensity of anti-KI67 antibody was statistically significantly upregulated in co-cultured wildtype organoids relative to STAG2 mutant organoids. Scale bars are 50µm. All experiments were performed with N = 3 biological replicates.

    Article Snippet: Primary antibodies used included rabbit anti-human STAG2 antibody (1:100, 19837–1-AP, Proteintech, USA), mouse anti-human KI67 antibody (1:500, 66555–6-Ig, Proteintech, USA), mouse anti-human P53 antibody (1:400, 60283–2-Ig, Proteintech, USA), mouse anti-human CCND1 antibody (1:100, 60186–1-Ig, Proteintech, USA), mouse anti-human TERT antibody (1: 100, MA5−16033, Invitrogen, USA), mouse anti-human KRAS antibody (1:250, 415700, Invitrogen, USA), and mouse anti-human TNFα antibody (1:50, MA5−23720, Invitrogen, USA).

    Techniques: Mutagenesis, Immunofluorescence, Staining, Cell Culture

    Figure 3. miR-623 directly targets cyclin D1 (CCND1) in GC. (A) Wild-type (WT) and mutated (MUT) miR-623 binding sequences in the 3¢-untranslated region (3¢-UTR) of CCND1. (B) RT-qPCR and (C) Western blot were performed to determine the mRNA and protein levels of CCND1 in SGC-7901 and BGC-823 cells transfected with miR-623 mimic or miR-NC. *p < 0.05 compared with miR-NC. miR-623 or miR-NC was transfected in (D) SGC-7901 and (E) BGC-823 cells with psiCHECK-WT-CCND1-3¢-UTR or psiCHECK-MUT-CCND1-3¢-UTR. Relative luciferase activity levels were measured at 48 h posttransfection. *p < 0.05 compared with miR-NC.

    Journal: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

    Article Title: MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer

    doi: 10.3727/096504018x15193469240508

    Figure Lengend Snippet: Figure 3. miR-623 directly targets cyclin D1 (CCND1) in GC. (A) Wild-type (WT) and mutated (MUT) miR-623 binding sequences in the 3¢-untranslated region (3¢-UTR) of CCND1. (B) RT-qPCR and (C) Western blot were performed to determine the mRNA and protein levels of CCND1 in SGC-7901 and BGC-823 cells transfected with miR-623 mimic or miR-NC. *p < 0.05 compared with miR-NC. miR-623 or miR-NC was transfected in (D) SGC-7901 and (E) BGC-823 cells with psiCHECK-WT-CCND1-3¢-UTR or psiCHECK-MUT-CCND1-3¢-UTR. Relative luciferase activity levels were measured at 48 h posttransfection. *p < 0.05 compared with miR-NC.

    Article Snippet: In this study, mouse anti-human monoclonal CCND1 (1:1,000 dilution; Catalog No. sc-8396) and mouse antihuman monoclonal b-actin (1:1,000 dilution; Catalog No. sc-81178) primary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). b-Actin was utilized as a loading control for protein level normalization.

    Techniques: Binding Assay, Quantitative RT-PCR, Western Blot, Transfection, Luciferase, Activity Assay

    Figure 4. CCND1 overexpression in GC tissues is inversely correlated with miR-623 level. (A) RT-qPCR and (B) Western blot were applied to measure the mRNA and protein expression levels of CCND1 in GC tissues and adjacent normal tissues, respectively. *p < 0.05 compared with normal tissues. (C) The association between CCND1 mRNA and miR-623 levels in GC tissues was assessed through Spearman’s correlation analysis. r = −0.5849, p = 0.0005.

    Journal: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

    Article Title: MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer

    doi: 10.3727/096504018x15193469240508

    Figure Lengend Snippet: Figure 4. CCND1 overexpression in GC tissues is inversely correlated with miR-623 level. (A) RT-qPCR and (B) Western blot were applied to measure the mRNA and protein expression levels of CCND1 in GC tissues and adjacent normal tissues, respectively. *p < 0.05 compared with normal tissues. (C) The association between CCND1 mRNA and miR-623 levels in GC tissues was assessed through Spearman’s correlation analysis. r = −0.5849, p = 0.0005.

    Article Snippet: In this study, mouse anti-human monoclonal CCND1 (1:1,000 dilution; Catalog No. sc-8396) and mouse antihuman monoclonal b-actin (1:1,000 dilution; Catalog No. sc-81178) primary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). b-Actin was utilized as a loading control for protein level normalization.

    Techniques: Over Expression, Quantitative RT-PCR, Western Blot, Expressing

    Figure 5. CCND1 overexpression reverses the effects of miR-623 on GC cells. (A) CCND1 protein expression was detected in SGC- 7901 and BGC-823 cells cotransfected with miR-623 mimic and pcDNA3.1 or pcDNA3.1-CCND1 through Western blot. *p < 0.05 compared with miR-NC. #p < 0.05 compared with miR-623 mimics + pDNA3.1-CCND1. CCK-8 assay (B), cell chemosensitivity assay (C), and flow cytometry analysis of cell apoptosis (D) were performed to determine cell proliferation, chemosensitivity to 5-FU, and apoptosis induced by 5-FU in differently treated SGC-7901 and BGC-823 cells, respectively. *p < 0.05 compared with miR-NC. #p < 0.05 compared with miR-623 mimics + pcDNA3.1-CCND1.

    Journal: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

    Article Title: MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer

    doi: 10.3727/096504018x15193469240508

    Figure Lengend Snippet: Figure 5. CCND1 overexpression reverses the effects of miR-623 on GC cells. (A) CCND1 protein expression was detected in SGC- 7901 and BGC-823 cells cotransfected with miR-623 mimic and pcDNA3.1 or pcDNA3.1-CCND1 through Western blot. *p < 0.05 compared with miR-NC. #p < 0.05 compared with miR-623 mimics + pDNA3.1-CCND1. CCK-8 assay (B), cell chemosensitivity assay (C), and flow cytometry analysis of cell apoptosis (D) were performed to determine cell proliferation, chemosensitivity to 5-FU, and apoptosis induced by 5-FU in differently treated SGC-7901 and BGC-823 cells, respectively. *p < 0.05 compared with miR-NC. #p < 0.05 compared with miR-623 mimics + pcDNA3.1-CCND1.

    Article Snippet: In this study, mouse anti-human monoclonal CCND1 (1:1,000 dilution; Catalog No. sc-8396) and mouse antihuman monoclonal b-actin (1:1,000 dilution; Catalog No. sc-81178) primary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). b-Actin was utilized as a loading control for protein level normalization.

    Techniques: Over Expression, Expressing, Western Blot, CCK-8 Assay, Flow Cytometry

    Figure 3. CCND1 is a direct target of miR‑720 in pancreatic cancer. (A) Wild type and mutant of putative miR‑720 binding sites in the 3'‑untranslated region (3'‑UTR) of CCND1. (B) Relative luciferase activities in Panc‑1 and Sw1990 cells transfected with miR‑720 mimics or NC, together with pMIR‑CCND1‑3'‑UTR WT or pMIR‑CCND1‑3'‑UTR MUT. *P<0.05 compared with NC. (C and D) RT‑qPCR and Western blot analyses showed that miR‑720 overexpression decreased CCND1 mRNA and protein expression levels in Panc‑1 and Sw1990 cells. *P<0.05 compared with NC.

    Journal: Molecular medicine reports

    Article Title: MicroRNA‑720 inhibits pancreatic cancer cell proliferation and invasion by directly targeting cyclin D1.

    doi: 10.3892/mmr.2017.7732

    Figure Lengend Snippet: Figure 3. CCND1 is a direct target of miR‑720 in pancreatic cancer. (A) Wild type and mutant of putative miR‑720 binding sites in the 3'‑untranslated region (3'‑UTR) of CCND1. (B) Relative luciferase activities in Panc‑1 and Sw1990 cells transfected with miR‑720 mimics or NC, together with pMIR‑CCND1‑3'‑UTR WT or pMIR‑CCND1‑3'‑UTR MUT. *P<0.05 compared with NC. (C and D) RT‑qPCR and Western blot analyses showed that miR‑720 overexpression decreased CCND1 mRNA and protein expression levels in Panc‑1 and Sw1990 cells. *P<0.05 compared with NC.

    Article Snippet: Subsequently, the membranes were blocked by 5% non-fat milk in Tris-based saline-Tween 20 (TBST) for 1 h at room temperature and blotted with primary antibodies: mouse anti-human CCND1 monoclonal antibody (sc-450; 1:1,000 dilution; Santa Cruz Biotechnology, CA, USA) or mouse anti-human GAPDH monoclonal antibody (sc-47724; 1:1,000 dilution; Santa Cruz Biotechnology, CA, USA).

    Techniques: Mutagenesis, Binding Assay, Luciferase, Transfection, Western Blot, Over Expression, Expressing

    Figure 4. Inverse correlation between miR‑720 and CCND1 in pancreatic cancer tissues. (A and B) MRNA and protein expression levels of CCND1 in pancreatic cancer tissues and matched adjacent normal pancreatic tissues were determined using RT‑qPCR and Western blot analyses. *P<0.05 compared with adjacent normal pancreatic tissues. T, pancreatic cancer tissues; N, adjacent normal pancreatic tissues. (C) Evaluation of the inverse correlation between miR‑720 and CCND1 in pancreatic cancer tissues by Spearman's correlation analysis (r=‑0.6105, P=0.0020).

    Journal: Molecular medicine reports

    Article Title: MicroRNA‑720 inhibits pancreatic cancer cell proliferation and invasion by directly targeting cyclin D1.

    doi: 10.3892/mmr.2017.7732

    Figure Lengend Snippet: Figure 4. Inverse correlation between miR‑720 and CCND1 in pancreatic cancer tissues. (A and B) MRNA and protein expression levels of CCND1 in pancreatic cancer tissues and matched adjacent normal pancreatic tissues were determined using RT‑qPCR and Western blot analyses. *P<0.05 compared with adjacent normal pancreatic tissues. T, pancreatic cancer tissues; N, adjacent normal pancreatic tissues. (C) Evaluation of the inverse correlation between miR‑720 and CCND1 in pancreatic cancer tissues by Spearman's correlation analysis (r=‑0.6105, P=0.0020).

    Article Snippet: Subsequently, the membranes were blocked by 5% non-fat milk in Tris-based saline-Tween 20 (TBST) for 1 h at room temperature and blotted with primary antibodies: mouse anti-human CCND1 monoclonal antibody (sc-450; 1:1,000 dilution; Santa Cruz Biotechnology, CA, USA) or mouse anti-human GAPDH monoclonal antibody (sc-47724; 1:1,000 dilution; Santa Cruz Biotechnology, CA, USA).

    Techniques: Expressing, Western Blot

    Figure 5. Upregulation of CCND1 prevents the inhibitory effects of miR‑720 on pancreatic cancer cells. (A) Protein expression of CCND1 in Panc‑1 and Sw1990 cells after transfection with miR‑720 mimics, NC or miR‑720 mimics, along with pcDNA 3.1‑CCND1. *P<0.05 compared with NC and miR‑720 mimics + pcDNA 3.1‑CCND1. (B and C) CCK8 assay and Matrigel invasion assay showed that CCND1 upregulation partly reversed the suppressive effects of miR‑720 on the proliferation and invasion of Panc‑1 and Sw1990 cells. *P<0.05 compared with NC and miR‑720 mimics + pcDNA 3.1‑CCND1.

    Journal: Molecular medicine reports

    Article Title: MicroRNA‑720 inhibits pancreatic cancer cell proliferation and invasion by directly targeting cyclin D1.

    doi: 10.3892/mmr.2017.7732

    Figure Lengend Snippet: Figure 5. Upregulation of CCND1 prevents the inhibitory effects of miR‑720 on pancreatic cancer cells. (A) Protein expression of CCND1 in Panc‑1 and Sw1990 cells after transfection with miR‑720 mimics, NC or miR‑720 mimics, along with pcDNA 3.1‑CCND1. *P<0.05 compared with NC and miR‑720 mimics + pcDNA 3.1‑CCND1. (B and C) CCK8 assay and Matrigel invasion assay showed that CCND1 upregulation partly reversed the suppressive effects of miR‑720 on the proliferation and invasion of Panc‑1 and Sw1990 cells. *P<0.05 compared with NC and miR‑720 mimics + pcDNA 3.1‑CCND1.

    Article Snippet: Subsequently, the membranes were blocked by 5% non-fat milk in Tris-based saline-Tween 20 (TBST) for 1 h at room temperature and blotted with primary antibodies: mouse anti-human CCND1 monoclonal antibody (sc-450; 1:1,000 dilution; Santa Cruz Biotechnology, CA, USA) or mouse anti-human GAPDH monoclonal antibody (sc-47724; 1:1,000 dilution; Santa Cruz Biotechnology, CA, USA).

    Techniques: Expressing, Transfection, CCK-8 Assay, Invasion Assay

    Figure 3. CCND1 is a potential target of miR-34a. (A) Schematic of the putative miR-34a binding site in the 3'-UTR region of CCND1 and interspecies conservation of seed matching sequences (gray box). (B) Diagram of CCND1 3'-UTR containing the reporter constructs. (C) Luciferase reporter assays in HEp-2 cells co-transfected with wt/mut 3'-UTR and miR-34a/miR-Ctrl as indicated. (D) Expression levels of CCND1 were tested after miR-34a transfection at 50 nM in HEp-2 cells by western blotting assay. *P<0.05 compared with the control. 3'-UTR, 3'-untranslated region.

    Journal: Oncology reports

    Article Title: Downregulation of miR-34a contributes to the proliferation and migration of laryngeal carcinoma cells by targeting cyclin D1.

    doi: 10.3892/or.2016.4823

    Figure Lengend Snippet: Figure 3. CCND1 is a potential target of miR-34a. (A) Schematic of the putative miR-34a binding site in the 3'-UTR region of CCND1 and interspecies conservation of seed matching sequences (gray box). (B) Diagram of CCND1 3'-UTR containing the reporter constructs. (C) Luciferase reporter assays in HEp-2 cells co-transfected with wt/mut 3'-UTR and miR-34a/miR-Ctrl as indicated. (D) Expression levels of CCND1 were tested after miR-34a transfection at 50 nM in HEp-2 cells by western blotting assay. *P<0.05 compared with the control. 3'-UTR, 3'-untranslated region.

    Article Snippet: After blocking for 1 h at room temperature and incubation overnight at 4̊C in Tris-buffered saline containing 0.05% Tween (TbsT) with 5% milk, the membranes were incubated with mouse monoclonal antibody against human CCND1 (Cell Signaling Technology, Danvers, MA, USA) or tubulin (Sigma-Aldrich) as a protein loading control, followed by horseradish peroxidase (HRp)-conjugated goat-anti-mouse igg (Abcam), and the bands were detected using the Supersignal West Pico eCL chemiluminescence kit (pierce) and Kodak X-ray film (Eastman Kodak Co, Rochester, NY, USA).

    Techniques: Binding Assay, Construct, Luciferase, Transfection, Expressing, Western Blot, Control

    Figure 4. CCND1 is essential for LSCC proliferation and migration, and is involved in the miR-34a-induced effect. (A) Analysis of CCND1 protein expres- sion by western blot analysis. CCND1 protein was reduced by small interfering RNA (CCND1-siRNA) in the HEp-2 cells. (B) MTT assay showed that cell proliferation was inhibited in the HEp-2 cells after transfection with CCND1-siRNA, compared with the scrambled sequence (Ctrl-siRNA). (C) Apoptosis analysis of HEp-2 cells in response to CCND1-siRNA at 48 h, by FACS assay. (D) Analysis of the effect of CCND1-siRNA on the migration of HEp-2 cells by Transwell migration assay. (E) MTT assay shows the cell proliferation in HEp-2 cells co-transfected with miR-34a and wt/mut 3'-UTR-CCND1 compared with miR-Ctrl. *P<0.05 compared with the control. LSCC, laryngeal squamous cell carcinomas.

    Journal: Oncology reports

    Article Title: Downregulation of miR-34a contributes to the proliferation and migration of laryngeal carcinoma cells by targeting cyclin D1.

    doi: 10.3892/or.2016.4823

    Figure Lengend Snippet: Figure 4. CCND1 is essential for LSCC proliferation and migration, and is involved in the miR-34a-induced effect. (A) Analysis of CCND1 protein expres- sion by western blot analysis. CCND1 protein was reduced by small interfering RNA (CCND1-siRNA) in the HEp-2 cells. (B) MTT assay showed that cell proliferation was inhibited in the HEp-2 cells after transfection with CCND1-siRNA, compared with the scrambled sequence (Ctrl-siRNA). (C) Apoptosis analysis of HEp-2 cells in response to CCND1-siRNA at 48 h, by FACS assay. (D) Analysis of the effect of CCND1-siRNA on the migration of HEp-2 cells by Transwell migration assay. (E) MTT assay shows the cell proliferation in HEp-2 cells co-transfected with miR-34a and wt/mut 3'-UTR-CCND1 compared with miR-Ctrl. *P<0.05 compared with the control. LSCC, laryngeal squamous cell carcinomas.

    Article Snippet: After blocking for 1 h at room temperature and incubation overnight at 4̊C in Tris-buffered saline containing 0.05% Tween (TbsT) with 5% milk, the membranes were incubated with mouse monoclonal antibody against human CCND1 (Cell Signaling Technology, Danvers, MA, USA) or tubulin (Sigma-Aldrich) as a protein loading control, followed by horseradish peroxidase (HRp)-conjugated goat-anti-mouse igg (Abcam), and the bands were detected using the Supersignal West Pico eCL chemiluminescence kit (pierce) and Kodak X-ray film (Eastman Kodak Co, Rochester, NY, USA).

    Techniques: Migration, Western Blot, Small Interfering RNA, MTT Assay, Transfection, Sequencing, Transwell Migration Assay, Control

    Figure 5. miR-34a and CCND1 are inversely correlated in LSCC tissues. (A) Statistical quantification of the mRNA expression levels of CCND1 (analyzed with q-PCR) between LSCC and paired NAT specimen. The CCND1 level was normalized to GAPDH (P<0.01). (B) A scatter diagram shows an inverse correlation between miR-34a and CCND1 expression in the same set of LSCC tissues (Spearman's correlation analysis, r =-7604; P<0.0001). NATs, normal adjacent tissues; LSCC, laryngeal squamous cell carcinomas.

    Journal: Oncology reports

    Article Title: Downregulation of miR-34a contributes to the proliferation and migration of laryngeal carcinoma cells by targeting cyclin D1.

    doi: 10.3892/or.2016.4823

    Figure Lengend Snippet: Figure 5. miR-34a and CCND1 are inversely correlated in LSCC tissues. (A) Statistical quantification of the mRNA expression levels of CCND1 (analyzed with q-PCR) between LSCC and paired NAT specimen. The CCND1 level was normalized to GAPDH (P<0.01). (B) A scatter diagram shows an inverse correlation between miR-34a and CCND1 expression in the same set of LSCC tissues (Spearman's correlation analysis, r =-7604; P<0.0001). NATs, normal adjacent tissues; LSCC, laryngeal squamous cell carcinomas.

    Article Snippet: After blocking for 1 h at room temperature and incubation overnight at 4̊C in Tris-buffered saline containing 0.05% Tween (TbsT) with 5% milk, the membranes were incubated with mouse monoclonal antibody against human CCND1 (Cell Signaling Technology, Danvers, MA, USA) or tubulin (Sigma-Aldrich) as a protein loading control, followed by horseradish peroxidase (HRp)-conjugated goat-anti-mouse igg (Abcam), and the bands were detected using the Supersignal West Pico eCL chemiluminescence kit (pierce) and Kodak X-ray film (Eastman Kodak Co, Rochester, NY, USA).

    Techniques: Expressing

    Figure 5. miR-129-5p directly targets APC-mRNA at 39-UTR and protein expression of genes regulated by miR-129-5p. (A) The predicted miR-129-5p target site on the APC 39-UTR. (B) Luciferase reporter gene assay measuring interactions between miR-129-5p and its binding site on the 39UTR of APC in HEK293T cells. The expression of the APC reporter was significantly decreased 53% in miR-129-5p-transfected cells compared to control cells. *P,0.05. (C) Luciferase reporter gene assay for measuring interactions between miR-129-5p and 39UTR of the APC mutant in HEK293T cells. There was no significant difference between groups (P.0.05). Luciferase experiments were repeated 3 times. (D) APC expression in the cells treated with ASO-miR-129-5p was increased compared to that in the controls. *P,0.05. (E) cyclin D1 expression in the cells treated with ASO- miR-129-5p was lower compared to controls. *P,0.05. (F) c-myc expression in the cells treated with ASO-miR-129-5p was lower compared to controls. *P,0.05. doi:10.1371/journal.pone.0077829.g005

    Journal: PloS one

    Article Title: Down-regulation of miR-129-5p inhibits growth and induces apoptosis in laryngeal squamous cell carcinoma by targeting APC.

    doi: 10.1371/journal.pone.0077829

    Figure Lengend Snippet: Figure 5. miR-129-5p directly targets APC-mRNA at 39-UTR and protein expression of genes regulated by miR-129-5p. (A) The predicted miR-129-5p target site on the APC 39-UTR. (B) Luciferase reporter gene assay measuring interactions between miR-129-5p and its binding site on the 39UTR of APC in HEK293T cells. The expression of the APC reporter was significantly decreased 53% in miR-129-5p-transfected cells compared to control cells. *P,0.05. (C) Luciferase reporter gene assay for measuring interactions between miR-129-5p and 39UTR of the APC mutant in HEK293T cells. There was no significant difference between groups (P.0.05). Luciferase experiments were repeated 3 times. (D) APC expression in the cells treated with ASO-miR-129-5p was increased compared to that in the controls. *P,0.05. (E) cyclin D1 expression in the cells treated with ASO- miR-129-5p was lower compared to controls. *P,0.05. (F) c-myc expression in the cells treated with ASO-miR-129-5p was lower compared to controls. *P,0.05. doi:10.1371/journal.pone.0077829.g005

    Article Snippet: Primary antibodies included a mouse anti-human cyclin D1 (1:200, Zhongshan Golden Bridge Biotechnology, Beijing, China), a rabbit anti-human APC, and a rabbit anti-human c-myc (1:200, Boster, Wuhan, China).

    Techniques: Expressing, Luciferase, Reporter Gene Assay, Binding Assay, Transfection, Control, Mutagenesis

    Figure 6. Immunohistochemistry of APC, cyclin D1, and c-myc. (A) Intense cytoplasmic labelling of APC was observed in cells treated with ASO-miR-129-5p compared with that in GFP or untreated Hep-2 cell groups. (B) Immunohistochemical signals of cytoplasmic cyclin D1 were undetectable in the sections from the ASO-miR-129-5p group, while signal is robust in sections from the GFP and untreated groups. (C) Immunohistochemical signals of cytoplasmic c-myc were undetectable in the sections from the ASO-miR-129-5p group, while signal is robust in sections from the GFP and untreated groups. doi:10.1371/journal.pone.0077829.g006

    Journal: PloS one

    Article Title: Down-regulation of miR-129-5p inhibits growth and induces apoptosis in laryngeal squamous cell carcinoma by targeting APC.

    doi: 10.1371/journal.pone.0077829

    Figure Lengend Snippet: Figure 6. Immunohistochemistry of APC, cyclin D1, and c-myc. (A) Intense cytoplasmic labelling of APC was observed in cells treated with ASO-miR-129-5p compared with that in GFP or untreated Hep-2 cell groups. (B) Immunohistochemical signals of cytoplasmic cyclin D1 were undetectable in the sections from the ASO-miR-129-5p group, while signal is robust in sections from the GFP and untreated groups. (C) Immunohistochemical signals of cytoplasmic c-myc were undetectable in the sections from the ASO-miR-129-5p group, while signal is robust in sections from the GFP and untreated groups. doi:10.1371/journal.pone.0077829.g006

    Article Snippet: Primary antibodies included a mouse anti-human cyclin D1 (1:200, Zhongshan Golden Bridge Biotechnology, Beijing, China), a rabbit anti-human APC, and a rabbit anti-human c-myc (1:200, Boster, Wuhan, China).

    Techniques: Immunohistochemistry, Immunohistochemical staining